person · Reporting owner
Riggsbee Richard Bryan
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | June 12, 2026 | June 16, 2026 |
| NEOGEN CORPNEOG · Entity 4338 | CFO | August 14, 2026 | August 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,312 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 9,795 · Balance 39,312 F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.
NEOGEN CORP
Report date August 14, 2026 · Filed August 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,502 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 51,502 · Balance 51,502 F2: PSUs vest in total at the end of the three year anniversary date of the grant |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2036-08-14 | Direct | 261,702 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Grant · Acquired 261,702 · Balance 261,702 F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants
F2: PSUs vest in total at the end of the three year anniversary date of the grant
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date January 29, 2024 · Filed January 31, 2024
Section 16 reporting ended · disclosed 2024-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,812 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 291,812 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 15, 2026 00:53 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 261,702 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0000711377-26-000015 · primary_doc.xml · derivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,702 Underlying: Common Stock · 261,702 shares Expires 2036-08-14 F1 · derivative.exercise_date: Options vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| August 14, 2026 Filed Aug 15, 2026 00:53 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 51,502 | $11.65 | $599,998.30 |
DisclosureSEC source: 0000711377-26-000015 · primary_doc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,502 F2 · shares: PSUs vest in total at the end of the three year anniversary date of the grant Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:50 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 9,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-26-000001 · form4-06162026_090617.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,312 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 14:20 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 459,713 | $0.00 Strike: $6.29 | $0.00 |
DisclosureSEC source: 0000711377-25-000074 · primary_doc.xml · derivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,713 Underlying: Common Stock · 459,713 shares Expires 2025-11-03 F1 · derivative.exercise_date: Options vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 14:20 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 178,855 | $6.29 | $1,124,997.95 |
DisclosureSEC source: 0000711377-25-000074 · primary_doc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,855 F2 · shares: PSUs vest in total at the end of the three year anniversary date of the grant Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087415 · ownership.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,517 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on the earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 23:06 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · derivative · entry 4 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F4 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 23:06 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,414 F2 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 20, 2024 20:40 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950170-24-075649 · ownership.xml · derivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F3 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:06 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 9,760 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · derivative · entry 3 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,760 Underlying: Common Stock · 9,760 shares Expires 2034-06-13 F3 · derivative.exercise_date: 1/36th of the shares subject to this option shall vest on April 11, 2024 and 1/36th of the shares subject to the option shall vest monthly thereafter through March 11, 2027. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:06 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 6,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,844 F1 · shares: The reported securities are represented by restricted stock units which shall vest in three equal annual installments beginning on March 11, 2025. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:40 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 9,760 | $0.00 Strike: $14.61 | $0.00 |
DisclosureSEC source: 0000950170-24-075649 · ownership.xml · derivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,760 Underlying: Common Stock · 9,760 shares Expires 2034-06-13 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/36th of the shares subject to this option shall vest on April 11, 2024 and 1/36th of the shares subject to the option shall vest monthly thereafter through March 11, 2027. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 30,000 | $19.09 | $572,835.00 |
DisclosureSEC source: 0001621899-23-000014 · wk-form4_1701811156.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,812 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.62 to $19.27, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:12 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 30,000 | $15.69 | $470,622.00 |
DisclosureSEC source: 0001621899-23-000012 · wk-form4_1699045936.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,812 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $16.04, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,382 | $15.01 | $110,803.82 |
DisclosureSEC source: 0001621899-23-000010 · wk-form4_1696969324.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,812 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,954 | $15.01 | $74,359.54 |
DisclosureSEC source: 0001621899-23-000010 · wk-form4_1696969324.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,194 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,517 | $15.99 | $72,226.83 |
DisclosureSEC source: 0001621899-23-000008 · wk-form4_1695846764.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,148 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,307 | $23.72 | $125,882.04 |
DisclosureSEC source: 0001628280-23-009259 · wf-form4_167994883346896.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,665 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,622 | $23.72 | $85,913.84 |
DisclosureSEC source: 0001628280-23-009259 · wf-form4_167994883346896.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,972 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,074 | $22.91 | $93,335.34 |
DisclosureSEC source: 0001628280-23-009045 · wf-form4_167960326581990.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,594 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 43,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008323 · wf-form4_167899868751482.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,668 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:07 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 15,000 | $22.55 | $338,253.00 |
DisclosureSEC source: 0001621899-23-000005 · wf-form4_167788121229192.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,885 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 11,222 | $19.42 | $217,931.24 |
DisclosureSEC source: 0001621899-23-000003 · wf-form4_167701522597948.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,885 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 17, 2023. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 21:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 9,400 | $20.04 | $188,386.34 |
DisclosureSEC source: 0001621899-23-000002 · wf-form4_167450842679054.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,107 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.12, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 22:56 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 600 | $20.01 | $12,006.00 |
DisclosureSEC source: 0001621899-23-000001 · wf-form4_167416896780055.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 20,000 | $15.15 | $302,992.00 |
DisclosureSEC source: 0001621899-22-000008 · wf-form4_167226151057587.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,107 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.54, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:35 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,411 | $19.62 | $145,403.82 |
DisclosureSEC source: 0001628280-22-026253 · wf-form4_166552053717645.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,107 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:35 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,974 | $19.62 | $97,589.88 |
DisclosureSEC source: 0001628280-22-026253 · wf-form4_166552053717645.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,518 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,543 | $18.41 | $83,636.63 |
DisclosureSEC source: 0001628280-22-025563 · wf-form4_166431065748425.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,492 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022. Read SEC document |
| September 25, 2022 Filed Sep 27, 2022 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,263 | $18.69 | $98,365.47 |
DisclosureSEC source: 0001628280-22-025563 · wf-form4_166431065748425.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,035 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,056 | $24.89 | $76,063.84 |
DisclosureSEC source: 0001628280-22-023767 · wf-form4_166154532207583.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,298 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022. Read SEC document |
| August 15, 2022 Filed Aug 26, 2022 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GiftCommon Stock | 2,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-023767 · wf-form4_166154532207583.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,354 Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,323 | $25.32 | $134,778.36 |
DisclosureSEC source: 0001621899-22-000006 · edgardoc.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,504 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,633 | $25.32 | $91,987.56 |
DisclosureSEC source: 0001621899-22-000006 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,827 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 36,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-22-000004 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,460 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 18, 2022 Filed Feb 18, 2022 22:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 11,180 | $25.69 | $287,214.20 |
DisclosureSEC source: 0001621899-22-000002 · edgardoc.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,594 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 18, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 48,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-22-000002 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,774 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:52 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,419 | $30.88 | $229,098.72 |
DisclosureSEC source: 0001621899-21-000013 · edgardoc.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,765 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:52 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,979 | $30.88 | $153,751.52 |
DisclosureSEC source: 0001621899-21-000013 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,184 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021. Read SEC document |
| September 26, 2021 Filed Sep 27, 2021 23:33 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,541 | $33.31 | $151,260.71 |
DisclosureSEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,163 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 25, 2021 Filed Sep 27, 2021 23:33 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 11,907 | $33.31 | $396,622.17 |
DisclosureSEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,704 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 66,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-21-000009 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,611 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 01:53 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,058 | $34.81 | $106,448.98 |
DisclosureSEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 2 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,634 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021. Read SEC document |
| August 10, 2021 Filed Aug 27, 2021 01:53 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GiftCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,692 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 14,983 | $35.14 | $526,475.65 |
DisclosureSEC source: 0001621899-21-000006 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,942 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 32,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-21-000004 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,925 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 11,175 | $29.69 | $331,785.75 |
DisclosureSEC source: 0001621899-21-000002 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,151 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 12:02 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 44,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001621899-20-000012 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,326 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,653 | $13.04 | $86,755.12 |
DisclosureSEC source: 0001621899-20-000010 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,372 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 28, 2020 16:42 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,546 | $12.44 | $56,552.24 |
DisclosureSEC source: 0001621899-20-000008 · edgardoc.xml · nonDerivative · entry 4 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,025 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.